CONTENTS:
- Should public health bodies stop commissioning research from market research companies that serve the tobacco industry? [Editorial]. Brown J., Michie S., Raupach T., West R., p. 1-2.
- Is research in substance abuse undervalued? [Editorial]. Sindelar J.L., Strombotne K.L., p. 3-4.
- Addiction research centres and the nurturing of creativity: The Kurihama Medical and Addiction Centre - a profile. Tohyama T., Yokoyama A., Matsushita S., Higuchi S., p. 5-11.
- Conversation with Connie Weisner. 12-19.
- Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review. Feelemyer J., Des Jarlais D., Arasteh K., Abdul-Quader A.S., Hagan H., p. 20-32.
- Commentary on Freelemyer et al. (2014): Medication-assisted treatment in Africa - need is growing but response remains tepid. Obot I.S., p. 33-34.
- A systematic review of studies assessing the association between adherence to smoking cessation medication and treatment success. Raupach T., Brown J., Herbec A., Brose L., West R., p. 35-43.
- Acute alcohol-related dysfunction as a predictor of employment status in a longitudinal study of working-age men in Izhevsk, Russia. Cook S., DeStavola B.L., Saburova L., Leon D.A., p. 44-54.
- Legalization of Sunday alcohol sales and alcohol consumption in the United States. Yörük B.K., p. 55-61.
- Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Fuster D., Cheng D.M., Quinn E.K., Nunes D., Saitz R., Samet J.H., et al., p. 62-70.
- Usefulness of indirect alcohol biomarkers for predicting recidivism of drunk-driving among previously convicted drunk-driving offenders: results from the Recidivism Of Alcohol-impaired Driving (ROAD) study. Maenhout T.M., Poll A., Vermassen T., De Buyzere M.L., Delanghe J.R., the R.S.G., p. 71-78.
- Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Hser Y.-I., Saxon A.J., Huang D., Hasson A., Thomas C., Hillhouse M., et al., p. 79-87.
- Commentary on Hser et al. (2014): To retain or not to retain - open questions in opioid maintenance therapy. Soyka M., Hillemacher T., p. 88-89.
- Causes of death in a cohort treated for opioid dependence between 1985 and 2005. Degenhardt L., Larney S., Randall D., Burns L., Hall W., p. 90-99.
- Commentary on Degenhardt et al. (2014): Cohort studies enhance the picture of drug-related deaths. Fugelstad A., p. 100-101.
- Non-medical use of prescription opioids during the transition to adulthood: a multi-cohort national longitudinal study. McCabe S.E., Schulenberg J.E., O'Malley P.M., Patrick M.E., Kloska D.D., p. 102-110.
- The relationship between cannabis outcome expectancies and cannabis refusal self-efficacy in a treatment population. Connor J.P., Gullo M.J., Feeney G.F.X., Kavanagh D.J., Young R.M., p. 111-119.
- A closer look at the evidence for sex differences in the genetic and environmental influences on gambling in the National Longitudinal Study of Adolescent health: from disordered to ordered gambling. Slutske W.S., Richmond-Rakerd L.S., p. 120-127.
- Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Chen L.-S., Bloom A.J., Baker T.B., Smith S.S., Piper M.E., Martinez M., et al., p. 128-137.
- Commentary on Chen et al. (2014): Another step on the road to clinical utility of pharmacogenetics for smoking cessation? David S.P., p. 138-139.
- Impact of the 2009 Taiwan Tobacco Hazards Prevention Act on smoking cessation. Chang F.-C., Sung H.-Y., Zhu S.-H., Chiou S.-T., p. 140-146.
- Did hardening occur among smokers in England from 2000 to 2010? Docherty G., McNeill A., Gartner C., Szatkowski L., p. 147-154.
- Tobacco use disorder and the risk of suicide mortality. Bohnert K.M., Ilgen M.A., McCarthy J.F., Ignacio R.V., Blow F.C., Katz I.R., p. 155-162.
- A second-class science? A defence of observational epidemiology to make causal inferences. Bell S., Britton A., p. 163-164.
- Second-class evidence for causality, not second-class science. Fekjaer H.O., p. 164-165.